What is the recommended management for acute exacerbation of interstitial lung disease?

Management of Acute Exacerbation of Interstitial Lung Disease

For acute exacerbation of ILD, initiate high-dose corticosteroids immediately (pulse intravenous methylprednisolone) combined with aggressive immunosuppression, while simultaneously ruling out infection and other reversible triggers. The specific treatment approach differs dramatically based on the underlying ILD subtype and disease phenotype.

Initial Assessment and Diagnosis

Acute exacerbation of ILD (AE-ILD) is defined as acute respiratory worsening with increased dyspnea, new ground-glass opacities or consolidation on imaging, and features consistent with diffuse alveolar damage—all occurring without an identifiable alternative cause 1. Before diagnosing AE-ILD, you must systematically exclude:

• Infection (bacterial pneumonia, viral pneumonitis, opportunistic infections)
• Pulmonary edema from cardiac causes
• Pulmonary embolism
• Pneumothorax
• Drug toxicity

These alternative diagnoses fall under the broader category of "acute respiratory worsening" (ARW) rather than true AE-ILD, and require entirely different management 1.

Disease-Specific Treatment Algorithms

For Rapidly Progressive ILD (RP-ILD)

The most aggressive approach is warranted here. For patients with rapidly progressive disease (progression from room air to high oxygen requirements within days to weeks):

• First-line: Pulse intravenous methylprednisolone 2
• Combination therapy is superior to monotherapy: Use upfront triple therapy (glucocorticoids + two immunosuppressants) for confirmed or suspected MDA-5 positive disease, or double/triple therapy for other RP-ILD 2
• Preferred immunosuppressants: Rituximab, cyclophosphamide, IVIG, mycophenolate, calcineurin inhibitors (CNI), or JAK inhibitors 2
• Avoid: Nintedanib, pirfenidone, tocilizumab, TNF inhibitors, and plasma exchange in RP-ILD 2

For Systemic Sclerosis-Associated ILD (SSc-ILD)

Never use glucocorticoids as first-line therapy in SSc-ILD due to the risk of scleroderma renal crisis, particularly at doses >15 mg prednisone equivalent daily 2. For acute exacerbation:

• Strongly recommend against long-term glucocorticoids 2
• Preferred agents: Mycophenolate, rituximab, cyclophosphamide, or nintedanib 2
• Consider early referral for stem cell or lung transplantation 2

For Idiopathic Pulmonary Fibrosis (IPF)

Despite very low-quality evidence, high-dose corticosteroids remain the standard approach for acute exacerbation of IPF, based on the high mortality without treatment and anecdotal reports of benefit 3. Intravenous corticosteroids up to 1 gram per day have been reported 3.

For Inflammatory Myopathy-Associated ILD (IIM-ILD)

Use more aggressive immunosuppression:

• First-line options: JAK inhibitors and calcineurin inhibitors are conditionally recommended specifically for IIM-ILD 2
• For progression: Add IVIG as a treatment option 2
• These agents are specifically recommended against in other SARD-ILD subtypes 2

For Other Connective Tissue Disease-Associated ILD

• Short-term glucocorticoids (≤3 months) are conditionally recommended for SARD-ILD other than SSc 2
• Preferred immunosuppressants: Mycophenolate (first choice), followed by azathioprine, rituximab, or cyclophosphamide 2

Respiratory Support Strategy

Initiate high-flow nasal cannula (HFNC) early to avoid progression to invasive mechanical ventilation 4, 5. The respiratory support escalation should follow this sequence:

1. High-flow nasal cannula (first-line for severe hypoxemia) 5
2. Noninvasive ventilation (for worsening hypoxemia/hypercapnia) 5
3. Invasive mechanical ventilation (only if absolutely necessary, as mortality remains extremely high) 5, 6

If Mechanical Ventilation Is Required:

• Use lung-protective ventilation: Low tidal volumes (6 mL/kg ideal body weight) 5
• High PEEP may be harmful: Associated with increased mortality in ILD patients 5
• Consider prone positioning for severe hypoxemia 5
• Target lowest FiO₂ that maintains safe oxygen saturation 7

Critical Pitfalls to Avoid

Do not delay corticosteroids while waiting for diagnostic confirmation in suspected AE-ILD—the mortality is too high to wait. However, obtain cultures and consider bronchoalveolar lavage if safe to do so, as infection is a common trigger and mimicker 4, 8.

Do not use antifibrotic agents (nintedanib, pirfenidone) for acute exacerbation treatment 2. While they may reduce the risk of future exacerbations when used chronically 7, 9, they have no role in acute management.

Avoid fluid overload: Careful fluid management is essential, as these patients have limited respiratory reserve 5.

Advanced Therapies and Transplant Considerations

For severe refractory cases:

• ECMO is reserved for the most severe cases but carries very high risk 5, 8
• Early referral for lung transplantation is essential for RP-ILD patients, as outcomes are better with earlier rather than later referral 2
• Initiate palliative care discussions early given the high mortality, even with aggressive treatment 8

Prognosis

Despite all interventions, mortality remains extremely high in AE-ILD 1, 5, 9. All cases in recent case series were fatal despite treatment 9, emphasizing the critical importance of prevention through chronic antifibrotic therapy when appropriate and early recognition of exacerbations.